ITEOS THERAPEUTICS INC (ITOS)

1. Introduction

ITEOS Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated immuno-oncology therapies. Headquartered in Cambridge, Massachusetts, with a research center in Gosselies, Belgium, ITEOS leverages insights into the tumor microenvironment and immunosuppressive pathways to design novel oncology candidates.

2. Corporate Structure

• Founded: 2011 (spin-off of Ludwig Cancer Research and the de Duve Institute)
• Headquarters: Cambridge, Massachusetts, USA
• Research Center: Gosselies, Belgium
• Industry: Biotechnology Research
• Company Size: 51–200 employees
• Leadership:
  • Michel Detheux, Ph.D. – Chief Executive Officer and President
  • Michel Detheux, Ph.D. – Appointed Chairman of the Board

3. Recent Developments and News

Clinical and Preclinical Updates

• In April 2025, two poster presentations on preclinical data for EOS-215 (anti-TREM2 antibody) and a novel PTPN1/2 inhibitor were delivered at the AACR Annual Meeting (#AACR2025).
• On May 12–13, 2025, ITEOS participated in the PEGS Boston Summit, discussing:
  • New mechanisms of adenosine-mediated immunosuppression and EOS-984
  • Advances in TCR-based bispecific engagers
  • Synthetic neoantigens and AI-driven protein engineering
• In May 2025, ITEOS announced its first-quarter 2025 financial results and a business update:
  • GALAXIES Lung-201 interim data anticipated in 2Q 2025
  • Initiation of patient dosing in TRM-010 (EOS-215) Phase 1/1b dose-escalation and expansion cohort trial
  • Two poster presentations at AACR on TREM2 mAb and PTPN1/2 inhibitor

Press Releases

• In May 2025, ITEOS reported topline interim results from the GALAXIES Lung-201 study of belrestotug (EOS-448) plus dostarlimab, noting the study did not meet predefined criteria for meaningful improvement in progression-free survival.

SEC Filings and Ownership Disclosures

• On May 16, 2025, EcoR1 Capital, LLC disclosed 10,688,978 shares (27.9% of outstanding stock) under Schedule 13D, indicating shared voting and dispositive power.
• On May 19, 2025, RA Capital Management, L.P. filed a Schedule 13D/A reporting 2,134,806 shares (4.9% of outstanding stock) with shared voting power.
• On May 28, 2025, ITEOS filed an 8-K (Items 2.05, 5.02, 7.01, 9.01) with material business updates.

4. Financial and Strategic Analysis

Stock and Valuation Metrics (as of 2025-05-28)

Metric	Value
Ticker	ITOS
Exchange	NAS
Price	$10.7212
Daily Change	+25.69%
Volume	1,402,097
52-Week Range	$4.80 – 18.13
Market Cap	$326.48 M
Price/Sales (ttm)	10.31
Price/Book (mrq)	0.58
Total Cash (mrq)	$520.37 M
Total Debt/Equity (mrq)	0.90%
EPS (ttm)	−3.05
Beta (5Y monthly)	1.39

Pipeline Overview

• Belrestotug (EOS-448) – anti-TIGIT antibody
  • Combination with dostarlimab in 1L NSCLC PDL1-high
    • GALAXIES Lung-301 (Phase 3, planned)
    • GALAXIES Lung-201 (Phase 2, active)
  • Combination with dostarlimab + CD96 in 1L HNSCC PDL1+ (GALAXIES H&N-202, Phase 2, active)
  • Combination with dostarlimab in 1L HNSCC PDL1-high/low (TIG-006, Phase 2, active)
• EOS-984 – adenosine pathway inhibitor
  • Monotherapy + pembrolizumab in advanced malignancies (APT-008, Phase 1, planned)
• EOS-215 – anti-TREM2 antibody
  • Monotherapy in advanced malignancies (TRM-010, Phase 1, planned)

Strategic Considerations

• Investor Activism: Significant stakes held by EcoR1 Capital and RA Capital may influence governance and strategic direction.
• Regulatory Pathways: Multiple Phase 2 and planned Phase 3 trials position ITEOS for potential registrational data in NSCLC and HNSCC.
• Partnerships and Collaborations: Academic collaborations, including MIT Koch Institute, support novel approaches to immune-oncology.

5. Market Position and Industry Context

• Immuno-Oncology Competition: The oncology market includes checkpoint inhibitors (PD-1/PD-L1), costimulatory targets (TIGIT), and adenosine pathway agents. ITEOS’s differentiated candidates aim to address immunosuppression via novel mechanisms.
• Clinical-Stage Focus: With no commercial products to date, value realization is contingent on trial outcomes, regulatory approvals, and potential partnerships.
• Financial Runway: A cash balance of $520 M (mrq) and low debt-to-equity ratio support ongoing R&D activities. Operational leverage remains tied to clinical milestones.

tl;dr

• Stock increased 25.69% to $10.72 on May 28, 2025, on a volume of 1.4 M shares.
• EcoR1 Capital holds a 27.9% stake; RA Capital holds 4.9%.
• In May 2025, topline GALAXIES Lung-201 interim data did not meet PFS criteria.
• Q1 2025 results announced in May 2025: GALAXIES Lung-201 interim data due in 2Q 2025; TRM-010 dosing initiated.
• Multiple Phase 2 trials active; Phase 3 planned for belrestotug combinations.
• Upcoming catalysts include GALAXIES Lung-301 initiation and APT-008 Phase 1 start.